Ionis Pharmaceuticals Inc. diskutieren
Ionis Pharmaceuticals Inc.
WKN: A2ACMZ / Symbol: IONS / Name: Ionis Pharmaceuticals / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
68,00 €
0,21 %
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Barclays PLC from $57.00 to $58.00. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Wells Fargo & Company from $77.00 to $82.00. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at HC Wainwright from $65.00 to $70.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Piper Sandler from $62.00 to $65.00. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Citigroup Inc. from $65.00 to $69.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $55.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at HC Wainwright from $70.00 to $95.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Needham & Company LLC from $55.00 to $70.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Jefferies Financial Group Inc. from $83.00 to $96.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $70.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Barclays PLC from $58.00 to $78.00. They now have an "overweight" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $40.00 to $45.00. They now have a "sell" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Citigroup Inc. from $69.00 to $84.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Royal Bank Of Canada from $70.00 to $80.00. They now have an "outperform" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Guggenheim from $90.00 to $92.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its price target raised by analysts at Bank of America Corporation from $81.00 to $83.00. They now have a "buy" rating on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $95.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for IONS provided by MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $90.00 price target on the stock.
Ratings data for IONS provided by MarketBeat
Neueste Beiträge
Jefferies_Financial_ in BankUnited Inc. diskutieren